{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:49:16Z","timestamp":1792158556214,"version":"4.4.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Antiobesity medications (AOMs) are increasingly utilized in patients before and after bariatric surgery. However, patients experience challenges to initiating and continuing these medications, leading to high real-world rates of discontinuation. We describe collaboration between an ambulatory care pharmacy service and bariatric surgeons as an opportunity to enhance patient care and medication access, with the collaboration encompassing ambulatory care pharmacists, pharmacy technicians, surgeons, advanced practice providers, and clinic support staff. The strategies employed to design, implement, and optimize patient care to meet the increasing demand for support with AOMs are discussed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The workflow incorporated key activities from highly diverse existing ambulatory care pharmacy and bariatric surgery practices. Resources utilized included an electronic pharmacy referral, collaborative practice agreements, and facilitation of medication access, including through completion of prior authorizations. Enhancements focused on coordination of visits to stagger the timing of follow-up visits, providing support to patients through insurance and coverage challenges, and communication to allow the pharmacy team to focus on all medication-related challenges while triaging other concerns to the multidisciplinary team. A pilot program to assess feasibility was implemented with a single pharmacist in August 2022, and the workflow was expanded by the end of 2024 to include 4 ambulatory care pharmacists and 2 pharmacy technicians collaborating with every bariatric surgeon in a large academic health system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The collaboration created a workflow to support an interdisciplinary standard of care for patients utilizing AOMs before and after bariatric surgery. This implementation approach can serve as a roadmap for other healthcare systems to support use of AOMs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxag307","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:44:58Z","timestamp":1790275498000},"source":"Crossref","is-referenced-by-count":0,"title":["Use of antiobesity medications in a bariatric surgery population: A collaborative approach with ambulatory care pharmacy services"],"prefix":"10.1093","author":[{"given":"Veronica","family":"Arceri","sequence":"first","affiliation":[{"name":"Yale New Haven Health System , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Lee","sequence":"additional","affiliation":[{"name":"Yale New Haven Health System , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Morton","sequence":"additional","affiliation":[{"name":"Bariatric and Minimally Invasive Surgery, Yale School of Medicine, New Haven, CT, and Yale New Haven Health System , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Renauer","sequence":"additional","affiliation":[{"name":"Yale New Haven Health System , New Haven, CT ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"2026101609010882200_zxag307-B1","author":"Centers for Disease Control and Prevention"},{"key":"2026101609010882200_zxag307-B2","doi-asserted-by":"publisher","first-page":"q1645","DOI":"10.1136\/bmj.q1645","article-title":"GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment","volume":"386","author":"Mahase","year":"2024","journal-title":"BMJ"},{"issue":"5","key":"2026101609010882200_zxag307-B3","doi-asserted-by":"publisher","first-page":"e204803","DOI":"10.1001\/jamanetworkopen.2020.4803","article-title":"Association of preoperative body weight and weight loss with risk of death after bariatric surgery","volume":"3","author":"Sun","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2026101609010882200_zxag307-B4","doi-asserted-by":"publisher","first-page":"e2413172","DOI":"10.1001\/jamanetworkopen.2024.13172","article-title":"GLP-1 receptor agonist discontinuation among patients with obesity and\/or type 2 diabetes","volume":"7","author":"Do","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2026101609010882200_zxag307-B5","doi-asserted-by":"publisher","first-page":"e2457349","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2026101609010882200_zxag307-B6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.55481\/2578-3750.1195","article-title":"How low can we go: evaluation of a pharmacist-led weight loss management program","volume":"7","author":"Rubi","year":"2024","journal-title":"Nurs Health Sci Res J"},{"issue":"2","key":"2026101609010882200_zxag307-B7","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1093\/fampra\/cmac110","article-title":"Evaluation of a pharmacist\u2019s impact on the use of glucagon-like peptide-1 receptor agonists for weight management in a family medicine setting","volume":"40","author":"Crocetta","year":"2023","journal-title":"Fam Pract"},{"issue":"22","key":"2026101609010882200_zxag307-B8","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1093\/ajhp\/zxae111","article-title":"The pharmacist\u2019s role in optimizing medication management before, during, and after minimally invasive and bariatric surgery","volume":"81","author":"Ebbitt","year":"2024","journal-title":"Am J Health-Syst Pharm"},{"issue":"11","key":"2026101609010882200_zxag307-B9","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1002\/jac5.1512","article-title":"Clinical review and role of clinical pharmacists in obesity management: an opinion of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy","volume":"4","author":"Clements","year":"2021","journal-title":"J Am Coll Clin Pharm"},{"issue":"22","key":"2026101609010882200_zxag307-B10","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1093\/ajhp\/zxac209","article-title":"Implementation of an integrated pharmacist collaborative care model in specialty disease state clinics","volume":"79","author":"Stroedecke","year":"2022","journal-title":"Am J Health-Syst Pharm"},{"issue":"13","key":"2026101609010882200_zxag307-B11","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1093\/ajhp\/zxad091","article-title":"Implementation of an integrated ambulatory care pharmacist collaborative care workflow model in specialty clinics in a large academic health system","volume":"80","author":"Lee","year":"2023","journal-title":"Am J Health-Syst Pharm"},{"issue":"12","key":"2026101609010882200_zxag307-B12","doi-asserted-by":"publisher","first-page":"9509","DOI":"10.1007\/s00464-023-10387-1","article-title":"Use of GLP-1 agonists in high risk patients prior to bariatric surgery: a cohort study","volume":"37","author":"Ilanga","year":"2023","journal-title":"Surg Endosc"},{"issue":"3","key":"2026101609010882200_zxag307-B13","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41366-024-01461-2","article-title":"Post metabolic bariatric surgery weight regain: the importance of GLP-1 levels","volume":"49","author":"\u00c7al\u0131k Ba\u015faran","year":"2025","journal-title":"Int J Obes"},{"key":"2026101609010882200_zxag307-B14","author":"Food and Drug Administration"},{"issue":"3","key":"2026101609010882200_zxag307-B15","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.soard.2016.12.005","article-title":"ASMBS position statement on postprandial hyperinsulinemic hypoglycemia after bariatric surgery","volume":"13","author":"Eisenberg","year":"2017","journal-title":"Surg Obes Relat Dis"},{"issue":"1","key":"2026101609010882200_zxag307-B16","doi-asserted-by":"publisher","first-page":"e2457349","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2026101609010882200_zxag307-B17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1001\/jama.2024.22284","article-title":"Discontinuation of glucagon-like peptide-1 receptor agonists","volume":"333","author":"Khan","year":"2025","journal-title":"JAMA"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag307\/71383533\/zxag307.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxag307\/71383533\/zxag307.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:01:15Z","timestamp":1792155675000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article\/doi\/10.1093\/ajhp\/zxag307\/8834000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":17,"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxag307","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"article-number":"zxag307"}}